Email Us
View Reports

Gene Therapy Market

Gene Therapy Market – By Region (North America, Europe, Asia Pacific, Latin America and Middle East & Africa) – Size, Share, Growth, Trends and Forecast to 2021

  • ID : 83447406  |  
  • Published : Jan-2019  |  
  • Region : Global  |  
  • Pages : 100   |  
  • Publisher : Polaris Market Research

Gene Therapy Market Size and Growth Rate:

According to a new report published by Research Cosmos, the global gene therapy market is anticipated to reach USD 4,300 million by 2021.

Gene Therapy Market Growth Drivers, Challenges and Opportunities:

The demand for gene therapy is primarily driven by continuous technological advancements and successful progression of several clinical trials targeting treatments with strong unmet need. Moreover, rising R&D spend on platform technologies by large and emerging biopharmaceutical companies and favorable regulatory environment will accelerate the clinical development and the commercial approval of gene therapies in the foreseeable future. Despite promise, the high cost of gene therapy represents a significant challenge for commercial adoption in the forecast period.

Gene therapy involves inactivating a mutated gene that is not functioning properly and introducing a new gene to assist in fighting a disease. Overall, the field of gene therapy continues to mature and advance with many products in development and nearing commercialization. For instance, Spark Therapeutics received approval of Luxturna, a rare form inherited blindness in December 2017. Gene therapy market in late 2017 also witnessed the approvals of Gilead/Kite Pharma’s Yescarta and Novartis’ Kymriah in the cancer therapeutic area.

Gene Therapy Market – Geographical Presence:

North America holds a dominating position in the global gene therapy market which is followed by Europe and the Asia Pacific. The U.S. has maximum number of clinical trials ongoing followed by Europe. Moreover, the field of gene therapy in the U.S. and Europe continues to gain investor attention driven by success of high visible clinical programs and the potential of gene therapy to address strong unmet need with meaningful commercial opportunity. Moreover, the increasing partnerships and alliances and the disruptive potential of gene therapy bodes well for the sector through the forecast period.

Key Findings from the study suggest products accessible in the market are much competitive and manufacturers are progressively concentrating on advancements to pick up an aggressive edge. Companies are in a stage of development of new items in order to guarantee simple implementation and connection with the current gene. The hospatility segment is anticipated to grow at a high growth rate over the forecast period with the expanding utilization of smart locks inferable from expanding security-related worries among clients amid their stay at the hotels. North America is presumed to dominate the global smart locks market over the forecast years and Asia Pacific region shows signs of high growth owing to the booming economies of India, and China.

Leading Market Players of Gene Therapy Market profiled in the report are:

  1. Novartis Pharmaceuticals Corporation
  2. Kite Pharma, Incorporated
  3. Spark Therapeutics, Inc
  4. GlaxoSmithKline
  5. Adaptimmune
  6. Bluebird bio
  7. Celgene
  8. Shanghai Sunway Biotech
  9. Shenzhen SiBiono GeneTech
  10. SynerGene Therapeutics

Detailed Segmentation of Gene Therapy Market:

Gene Therapy Market Analysis – By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa

Table of Contents

1. Gene Therapy Overview

1.1. History and Evolution of Gene Therapies

1.2. What is Gene Therapy

1.3. Types of Gene Therapy

1.4. Ex vivo and in vivo Approaches of Gene Therapy

1.5. RNAi Therapeutics

1.6. CAR-T Technology based Gene Therapy

1.7. Types of Vectors used for Gene Therapy

1.7.1. Viral

1.7.2. Non-Viral

2. Historical Marketed Gene Therapies [2003-2012]

2.1. Rexin-G (Epeius Biotechnologies Corporation)

2.2. Gendicine (SiBiono GeneTech Co., Ltd)

2.3. Neovasculgen [Human Stem Cells Institute (HSCI))

2.4. Glybera (UniQure Biopharma B.V.)

3. First Countries to get an access to Gene Therapies

3.1. Philippines for Rexin-G [2003]

3.2. China for Gendicine [2003]

3.3. Russia for Neovasculgen [2011]

3.4. Selected European Countries for Glybera [2012]

4. Marketed Gene Therapies [Approved in Recent Years]

4.1. KYMRIAH (tisagenlecleucel)

4.1.1. Therapy Description

4.1.2. Therapy Profile

4.1.2.1. Company

4.1.2.2. Approval Date

4.1.2.3. Mechanism of Action

4.1.2.4. Researched Indication

4.1.2.5. Vector Used

4.1.2.6. Vector Type

4.1.2.7. Technology

4.1.2.8. Others Development Activities

4.1.3. KYMRIAH Revenue Forecasted till 2021

4.2. YESCARTA (axicabtagene ciloleucel)

4.2.1. Therapy Description

4.2.2. Therapy Profile

4.2.2.1. Company

4.2.2.2. Approval Date

4.2.2.3. Mechanism of Action

4.2.2.4. Researched Indication

4.2.2.5. Vector Used

4.2.2.6. Vector Type

4.2.2.7. Technology

4.2.2.8. Others Development Activities

4.2.3. YESCARTA Revenue Forecasted till 2021

4.3. LUXTURNA (voretigene neparvovec-rzyl)

4.3.1. Therapy Description

4.3.2. Therapy Profile

4.3.2.1. Company

4.3.2.2. Approval Date

4.3.2.3. Mechanism of Action

4.3.2.4. Researched Indication

4.3.2.5. Vector Used

4.3.2.6. Vector Type

4.3.2.7. Technology

4.3.2.8. Others Development Activities

4.3.3. LUXTURNA Revenue Forecasted till 2021

4.4. STRIMVELIS

4.4.1. Therapy Description

4.4.2. Therapy Profile

4.4.2.1. Company

4.4.2.2. Approval Date

4.4.2.3. Mechanism of Action

4.4.2.4. Researched Indication

4.4.2.5. Vector Used

4.4.2.6. Vector Type

4.4.2.7. Technology

4.4.2.8. Others Development Activities

4.4.3. STRIMVELIS Revenue Forecasted till 2021

5. Comparison of current Regulatory Status for Gene Therapy Products

5.1. U.S

5.2. Europe

5.3. Japan

6. Emerging Gene Therapies [Phase III]

6.1. Gene Based Therapeutics under Development

6.2. Therapy Description

7. Indication of Focus in Gene Therapy

7.1. Cancer

7.2. Neurodegenerative Disorders

7.3. Lysosomal Storage Disorders (LSDs)

7.4. Ocular Diseases

7.5. Muscle Disorders

7.6. Anemia

7.7. Hemophilia

7.8. Severe Combined Immunodeficiency due to Adenosine Deaminase deficiency

8. Leading Companies

8.1. Novartis Pharmaceuticals Corporation

8.2. Kite Pharma, Incorporated

8.3. Spark Therapeutics, Inc

8.4. GlaxoSmithKline

8.5. Adaptimmune

8.6. Bluebird bio

8.7. Celgene

8.8. Shanghai Sunway Biotech

8.9. Shenzhen SiBiono GeneTech

8.10. SynerGene Therapeutics

8.11. Other Companies

9. The Future of Gene Therapy

10. Gene Therapy & Premium Pricing: Debates Intensifies with the approval of First Gene Therapies

11. Global Market Size of Gene Therapies (2016-2021)

11.1. Market Analysis by Marketed Gene Therapies

11.2. Market Analysis by Companies

11.3. Market Analysis by Indications

12. Market Size of Gene Therapies Broken Down by G7 Countries

12.1. United States

12.1.1. Market Size of Gene Therapies in United States (2016-2021)

12.1.2. New Therapies Launch and Sales Analysis (2016-2021)

12.1.3. Sales Analysis by Companies (2016-2021)

12.2. Germany

12.2.1. Market Size of Gene Therapies in Germany (2016-2021)

12.2.2. New Therapies Launch and Sales Analysis (2016-2021)

12.2.3. Sales Analysis by Companies (2016-2021)

12.3. France

12.3.1. Market Size of Gene Therapies in France (2016-2021)

12.3.2. New Therapies Launch and Sales Analysis (2016-2021)

12.3.3. Sales Analysis by Companies (2016-2021)

12.4. Italy

12.4.1. Market Size of Gene Therapies in Italy (2016-2021)

12.4.2. New Therapies Launch and Sales Analysis (2016-2021)

12.4.3. Sales Analysis by Companies (2016-2021)

12.5. Spain

12.5.1. Market Size of Gene Therapies in Spain (2016-2021)

12.5.2. New Therapies Launch and Sales Analysis (2016-2021)

12.5.3. Sales Analysis by Companies (2016-2021)

12.6. United Kingdom

12.6.1. Market Size of Gene Therapies in United Kingdom (2016-2021)

12.6.2. New Therapies Launch and Sales Analysis (2016-2021)

12.6.3. Sales Analysis by Companies (2016-2021)

12.7. Japan

12.7.1. Market Size of Gene Therapies in Japan (2016-2021)

12.7.2. New Therapies Launch and Sales Analysis (2016-2021)

12.7.3. Sales Analysis by Companies (2016-2021)

13. Factors Driving the Market of Gene Therapy

14. Factors Restraining the Market of Gene Therapy

16. Disclaimer

17. Sales Suppor

Purchase this Market Research Report

REACH OUT TO US

Call us on : +1 888 709 8757

Drop us an email at : info@researchcosmos.com

HAVE A QUESTION?